Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2008

01-05-2008 | Review

Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Author: H. Hof

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2008

Login to get access

Abstract

Growing numbers of patients receive azoles as prophylaxis or treatment for invasive fungal infections, begging the question of whether emergence of resistance will occur, as has been seen with bacteria. This review examines resistance pathways shared by bacteria and fungi, including alteration and overproduction of drug targets, changes in biosynthetic pathways, and enhanced drug efflux, and assesses whether such commonalities predict increased resistance to azoles. Important differences exist between the two kingdoms, including little, if any, horizontal transfer of extrachromosomal material across fungal species and a longer fungal generation time, thereby slowing vertical transfer of mutant traits. Further, no enzymatic modulation or inactivation of azoles has been reported in fungi. The newer broad-spectrum azoles posaconazole and voriconazole are active against the vast majority of yeasts and moulds and are likely to prevent the emergence of inherently resistant strains. Therefore, the likelihood for an explosion of fungal resistance is relatively low.
Literature
1.
Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D (2003) Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 22:406–419PubMedCrossRef
2.
National Nosocomial Infections Surveillance (NNIS) System Report (2004) Data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 32:470–485CrossRef
3.
Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53–59PubMedCrossRef
4.
Orsi GB, Scorzolini L, Franchi C, Mondillo V, Rosa G, Venditti M (2006) Hospital-acquired infection surveillance in a neurosurgical intensive care unit. J Hosp Infect 64:23–29PubMedCrossRef
5.
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39:309–317PubMedCrossRef
6.
Chamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 91:986–989PubMed
7.
Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K (1996) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33:23–32PubMedCrossRef
8.
Pfaller MA, Diekema DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42:4419–4431PubMedCrossRef
9.
Vazquez JA (2003) Invasive oesophageal candidiasis: current and developing treatment options. Drugs 63:971–989PubMedCrossRef
10.
Messer SA, Jones RN, Fritsche TR (2006) International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2003) J Clin Microbiol 44:1782–1787PubMedCrossRef
11.
Meis J, Petrou M, Bille J, Ellis D, Gibbs D, and the Global Antifungal Surveillance Group (2000) A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn Microbiol Infect Dis 36:215–223PubMedCrossRef
12.
Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Sousa A, del Palacio A, de Bedout C, Gibbs DL, and the Global Antifungal Surveillance Group (2003) Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 41:5623–5632PubMedCrossRef
13.
Rex JH, Rinaldi MG, Pfaller MA (1995) Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 39:1–8PubMed
14.
15.
Chen J, Li H, Li R, Bu D, Wan Z (2005) Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 55:31–37PubMedCrossRef
16.
Howard SJ, Webster I, Moore CB, Gardiner RE, Park S, Perlin DS, Denning DW (2006) Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 28:450–453PubMedCrossRef
17.
Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, de Pauw B, Meunier F (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071–1079PubMedCrossRef
18.
Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32:358–366PubMedCrossRef
19.
Boutati EI, Anaissie EJ (1997) Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 90:999–1008PubMed
20.
Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh DJ (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653PubMedCrossRef
21.
Perea S, Patterson TF (2002) Antifungal resistance in pathogenic fungi. Clin Infect Dis 35:1073–1080PubMedCrossRef
22.
Cornely OA, Ullmann AJ, Karthaus M (2003) Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 101:3365–3372PubMedCrossRef
23.
Zervos MJ, Hershberger E, Nicolau DP, Ritchie DJ, Blackner LK, Coyle EA, Donnelly AJ, Eckel SF, Eng RHK, Hiltz A, Kyumjian AG, Krebs W, McDaniel A, Hogan P, Lubowski TJ (2003) Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000. Clin Infect Dis 37:1643–1648PubMedCrossRef
24.
Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP (2003) Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289:885–888PubMedCrossRef
25.
Opal SM, Medeiros AA (2006) Molecular mechanisms of antibiotic resistance in bacteria. In: Mandell GL, Bennett JE, Dolin R (eds) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Churchill Livingstone, Philadelphia, pp 253–270
26.
Sanglard D, Odds FC (2002) Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73–85PubMedCrossRef
27.
Akins RA (2005) An update on antifungal targets and mechanisms of resistance in Candida albicans. Med Mycol 43:285–318PubMedCrossRef
28.
Steinbach WJ, Stevens DA (2003) Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37(suppl 3):S157–S187PubMedCrossRef
29.
Vanden Bossche H, Willemsens G, Marichal P (1987) Anti-Candida drugs—the biochemical basis for their activity. Crit Rev Microbiol 15:57–72CrossRef
30.
Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FCS, Odds FC, Bossche HV (1999) Contribution of mutations in the cytochrome P450 14a-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701–2713PubMed
31.
Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM (2004) Three-dimensional models of wild-type and mutated forms of cytochrome P450 14a-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 48:568–574PubMedCrossRef
32.
Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez T, Bouza E (2006) Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. Med Mycol 44:575–578PubMedCrossRef
33.
Li X, Brown N, Chau AS, Lopez-Rebot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM (2004) Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 53:74–80PubMedCrossRef
34.
Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM (2004) Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother 48:2124–2131PubMedCrossRef
35.
Sanglard D (2002) Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol 5:379–385PubMedCrossRef
36.
Marichal P, Vanden Bossche H, Odds FC, Nobels G, Warnock DW, Timmerman V, van Broeckhoven C, Fay S, Mose-Larsen P (1997) Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 41:2229–2237PubMed
37.
Lopez-Ribot JL, McAtee RK, Lee LN, Kirkpatrick WR, White TC, Sanglard D, Patterson DF (1998) Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 42:2932–2937PubMed
38.
Barker KS, Crisp S, Wiederhold N, Lewis RE, Bareither B, Eckstein J, Barbuch J, Bard M, Rogers PD (2004) Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J Antimicrob Chemother 54:376–385PubMedCrossRef
39.
Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, Geller R, Wingard JR (1997) Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 41:196–199PubMed
40.
Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12:501–517PubMed
41.
Chau AS, Gurnani M, Hawkinson R, Laverdiere M, Cacciapuoti A, McNicholas PM (2005) Inactivation of sterol D5,6-desaturase attenuates virulence in Candida albicans. Antimicrob Agents Chemother 49:3646–3651PubMedCrossRef
42.
de Waard MA, Andrade AC, Hayashi K, Schoonbeek H-J, Stergiopoulos I, Zwiers L-H (2006) Impact of fungal drug transporters on fungicide sensitivity, multidrug resistance and virulence. Pest Manag Sci 62:195–207PubMedCrossRef
43.
Sipos G, Kuchler K (2006) Fungal ATP-binding cassette (ABC) transporters in drug resistance & detoxification. Curr Drug Targets 7:471–481PubMedCrossRef
44.
Cowen LE (2001) Predicting the emergence of resistance to antifungal drugs. FEMS Microbiol Lett 204:1–7PubMedCrossRef
45.
Coste A, Turner V, Ischer F, Morschhauser J, Forche A, Selmecki A, Berman J, Bille J, Sanglard D (2006) A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics 172:2139–2156PubMedCrossRef
46.
Sanglard D, Ischer F, Bille J (2002) Interactions of ravuconazole (RVZ) with yeast multidrug efflux transporters and different cytochrome P450 mutant forms. Presented at the 42nd interscience conference on antimicrobial agents and chemotherapy, 27–30 September, San Diego, California
47.
Anderson JB (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3:547–556PubMedCrossRef
48.
Brun S, Dalle F, Saulnier P, Renier G, Bonnin A, Chabasse D, Bouchara JP (2005) Biological consequences of petite mutations in Candida glabrata. J Antimicrob Chemother 56:307–314PubMedCrossRef
49.
Brun S, Berges T, Poupard P, Vauzelle-Moreau C, Renier G, Chabasse D, Bouchara JP (2004) Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother 48:1788–1796PubMedCrossRef
50.
Cowen LE, Nantel A, Whiteway MS, Thomas DY, Tessier DC, Kohn LM, Anderson JB (2002) Population genomics of drug resistance in Candida albicans. Proc Natl Acad Sci USA 99:9284–9289PubMedCrossRef
51.
Cowen LE, Kohn LM, Anderson JB (2001) Divergence in fitness and evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 183:2971–2978PubMedCrossRef
52.
Marr KA, White TC, van Burik JA, Bowden RA (1997) Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 25:908–910PubMedCrossRef
53.
Marr KA, Lyons CN, Rustad TR, Bowden RA, White TC (1998) Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother 42:2584–2589PubMed
54.
Martins MD, Lozano-Chiu M, Rex JH (1998) Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends towards reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Inf Dis 27:1291–1294CrossRef
55.
Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50:2009–2015PubMedCrossRef
56.
Redding S, Smith J, Farinacci G, Rinaldi M, Fothergill A, Rhine-Chalberg J, Pfaller M (1994) Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 18:240–242PubMed
57.
Barchiesi F, Arzeni D, Del Prete MS, Sinicco A, Fanconi Di Francesco L, Pasticci MB, Lamura L, Nuzzo MM, Burzacchini F, Coppola S, Chiodo F, Scalise G (1998) Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis. J Antimicrob Chemother 41:541–548PubMedCrossRef
58.
Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43:2155–2162PubMedCrossRef
59.
Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, Sobel JD, Powderly WG, Patterson TF, Wheat LJ, Stein DK, Dismukes WE, Filler SG; AIDS Clinical Trials Group Study Team 323; Mycoses Study Group Study Team 40 (2005) A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS clinical trials group study 323/mycoses study group study 40. Clin Infect Dis 41:1473–1480PubMedCrossRef
60.
Carrillo-Munoz A-J, Quindos G, Ruesga M, Alonso R, del Valle O, Hernandez-Molina JM, McNicholas P, Loeberberg D, Santos P (2005) Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55:317–319PubMedCrossRef
61.
Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M, Borghi V, Rumpianesi F, Esposito R (2006) Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 12:75–80PubMedCrossRef
62.
Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R (2006) Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 27:359–366PubMedCrossRef
63.
Munoz P, Sanchez-Somolinos M, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E (2005) Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 55:188–193PubMedCrossRef
64.
Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, Tiraboschi N, Nagy E, Gibbs DL; the Global Antifungal Surveillance Group (2005) Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 43:5848–5859PubMedCrossRef
65.
Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH (2000) A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46:229–234PubMedCrossRef
66.
Ghannoum MA, Kuhn DM (2002) Voriconazole: better chances for patients with invasive mycoses. Eur J Med Res 7:242–256PubMed
67.
Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo S, Greinix H, Azevedo W, Reddy W, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347PubMedCrossRef
68.
Cornely OA, Maertens J, Winston DJ, Perfect J, Ulmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359PubMedCrossRef
69.
Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli M, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346:225–234PubMedCrossRef
70.
Wingard JR (2004) Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clin Infect Dis 9(suppl 4):S176–S180CrossRef
71.
Knoke M (1999) Gastrointestinal microecology of humans and Candida [in German]. Mycoses 42(suppl 1):30–34PubMed
72.
Schauer F, Hanschke R (1999) Taxonomy and ecology of the genus Candida [in German]. Mycoses 42(suppl 1):12–21PubMed
73.
Pfaller MA, Messer SA, Houston A, Rangel-Frausto MS, Wiblin T, Blumberg HM, Edwards JE, Jarvis W, Martin MA, Neu HC, Saiman L, Patterson JE, Dibb JC, Roldan CM, Rinaldi MG, Wenzel RP (1998) National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn Microbiol Infect Dis 31:289–296PubMedCrossRef
74.
Hof H (2001) Critical annotations to the use of azole antifungals for plant protection. Antimicrob Agents Chemother 45:2987–2990PubMedCrossRef
75.
Meneau I, Sanglard D (2005) Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol 43(suppl 1):S307–S311PubMedCrossRef
Metadata
Title
Will resistance in fungi emerge on a scale similar to that seen in bacteria?
Author
H. Hof
Publication date
01-05-2008
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2008
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0451-9

Other articles of this Issue 5/2008

European Journal of Clinical Microbiology & Infectious Diseases 5/2008 Go to the issue

Brief Report

Repeated enzyme immunoassays have limited utility in diagnosing Clostridium difficile

Article

Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis

Concise Article

SCCmec and spa types of methicillin-resistant Staphylococcus aureus strains in Israel. Detection of SCCmec type V

Concise Article

Quick and reliable galactomannan detection in crude minced lung specimens from haematological patients with suspected invasive fungal infection: results from a case series

Article

Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor

Article

Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits